New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
10:01 EDTWDAY, RGLS, ICPT, AMBA, SSTK, MUSA, CHTR, ADT, BSMX, KYTH, ANFIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADT Corp. (ADT) initiated with a Buy at Citigroup... Ambarella (AMBA) initiated with a Buy at Deutsche Bank... Amira Nature Foods (ANFI) initiated with a Buy at Deutsche Bank... Charter (CHTR) initiated with an Underweight at Barclays... Intercept Pharmaceuticals (ICPT) initiated with a Buy at Needham... Kythera Biopharmaceuticals (KYTH) initiated with a Neutral at Goldman... Metals USA (MUSA) initiated with an Outperform at Wells Fargo... Regulus Therapeutics (RGLS) initiated with a Buy at Needham... Santander Mexico (BSMX) initiated with a Buy at Citigroup... Shutterstock (SSTK) initiated with a Buy at Jefferies... Workday (WDAY) initiated with a Buy at Canaccord.
News For ADT;AMBA;ANFI;CHTR;ICPT;KYTH;MUSA;RGLS;BSMX;SSTK;WDAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 13, 2014
07:54 EDTRGLSRegulus Therapeutics 2M share Block Trade priced at $18.25
Morgan Stanley acted as sole book running manager for the offering.
November 12, 2014
12:00 EDTICPTKOLs say 'remains to be seen' if OCA can get accelerated approval, says Leerink
Subscribe for More Information
11:55 EDTICPTIntercept not part of talks with journals, says Deutsche Bank
Subscribe for More Information
07:08 EDTADTADT Corp. sees FY15 recurring revenue growth 5%-6%
Subscribe for More Information
07:07 EDTADTADT Corp. reports Q4 EPS 55c ex-items, consensus 48c
Reports Q4 revenue $883M, consensus $878.52M.
November 11, 2014
15:25 EDTADTNotable companies reporting before tomorrow's open
Subscribe for More Information
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
November 10, 2014
16:22 EDTKYTHKythera reports Q3 EPS (99c), consensus (88c)
Cash, cash equivalents and marketable securities totaled $117.4M at September 30, which compares to $63.7M, of which $9.7M was restricted, at September 30, 2013. The company had net use of cash, cash equivalents and marketable securities of $17.2M in Q3 and, based on current operating plans, believes its existing cash, cash equivalents and marketable securities will allow it to fund its operating plan through at least the next 12 months. Given anticipated activities for the remainder of the year, the company expects to end 2014 with a cash balance of $95M-$100M.
15:06 EDTRGLSRegulus Therapeutics' RG-101 mentioned positively at BMO Capital
13:52 EDTCHTRCharter issues statement regarding White House Title II announcement
Charter Communications released the following statement in response to the White House Title II Announcement: "Charter Communications unambiguously supports an open Internet, which is vital for consumers and central to our continued success. The extraordinary growth of broadband service in the United States, which now reaches more than 70 million households, has largely been the result of the current regulatory environment. For these reasons, we strongly oppose the reclassification of broadband as a Title II service under the Telecommunications Act. Efforts to reclassify broadband ignore the fact that the current rules have encouraged billions of dollars of investment in our broadband infrastructure and Americans' access to open, fast, and reliable service has never been greater. Applying 1930's-era, rotary telephone legislation to a 21st century computer technology comes with significant risks to consumers. It is a solution in search of a problem and threatens to undermine continued investment to improve and expand our nation's broadband infrastructure."
12:24 EDTCHTROn The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday. The averages opened mixed, but very close to the flat line, and have continued to drift slowly higher from that point. There is little to stand in the way of the marketís drift, as the economic calendar is quiet, the earnings season is winding down, and the most closely watched geopolitical situations are currently status quo. ECONOMIC EVENTS: In the U.S., little of note was on the economic calendar. The Federal Reserve's newly introduced Labor Market Conditions Index was flat at 4 in October. The Fed started updating estimates of the LMCI every month beginning with last month. COMPANY NEWS: Shares of Netflix (NFLX) advanced about 1% after xxx President Barack Obama publicly urged the Federal Communications Commission to implement the "strongest possible rules" to protect net neutrality. In response, Verizon (VZ) said it supports the open Internet and continues to believe that the "light-touch regulatory approach in place for the past two decades has been central to the Internetís success," adding that it believes the reclassification Obama called for would "apply 1930s-era utility regulation to the Internet" and be a "radical reversal of course" that would threaten great harm to an open Internet, competition and innovation." A number of Internet Service Providers, including Comcast (CMCSA), Time Warner Cable (TWC), Charter (CHTR) and Cablevision (CVC), moved lower after Obama weighed in on the hot-button issue. MAJOR MOVERS: Among the notable gainers was Achillion Pharmaceuticals (ACHN), which rose 22% after the company presented data from the ongoing Phase 2 study of its Hepatitis C virus treatment at the Annual Meeting of the American Association for the Study of Liver Diseases, or AASLD. Also higher was Dean Foods (DF), which rose more than 13% after the dairy products distributorís third quarter results, as well as its fourth quarter and full year profit outlook, surpassed analystsí consensus estimates. Among the noteworthy losers was Rayonier (RYN), which dropped 13% after management determined that there was a material weakness in the company's internal controls, restated certain previously made financial statements, and cut its dividend reflecting expectations of reduced cash available for distribution due to lower expected annual harvest levels. INDEXES: Near midday, the Dow was up 18.55, or 0.11%, to 17,592.48, the Nasdaq was up 10.77, or 0.23%, to 4,643.30, and the S&P 500 was up 4.01, or 0.2%, to 2,035.93.
10:54 EDTRGLSRegulus hepatitis C drug not winning over doctors, TheStreet reports
Subscribe for More Information
10:14 EDTRGLSHigh option volume stocks
High option volume stocks: UN PAGP PHH RGLS DF URA CERS DNDN LGF CALL
10:06 EDTCHTRVerizon says utility Internet regulation would 'threaten great harm'
Subscribe for More Information
10:01 EDTCHTRTWC, Charter, Comcast drop after Obama calls for Internet regulation
Subscribe for More Information
09:45 EDTCHTRObama urges FCC to enact 'strongest possible rules' to protect net neutrality
Subscribe for More Information
09:43 EDTCHTRObama urges FCC to enact 'strongest possible rules' to protect net neutrality
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
07:23 EDTSSTKRBC Capital to hold a conference
Subscribe for More Information
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE Ė the first Phase 3 trial in PBC in two decades Ė are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use